GuangYuYuan Chinese Herbal Medicine Co., Ltd., a prominent player in the health care sector, specializes in the pharmaceutical industry. The company is headquartered in Xi’an, China, and is renowned for its extensive range of pharmaceutical products. These include Chinese raw material medicines, Western raw material medicines, tablets, capsules, injections, and other drug formulations. In addition to its core pharmaceutical operations, GuangYuYuan also offers advertising services, enhancing its market presence.
The company is publicly traded on the Shanghai Stock Exchange under the ticker symbol 600771. It has been a part of the public market since its Initial Public Offering (IPO) on October 16, 1996. As of the latest financial data, GuangYuYuan’s market capitalization stands at approximately 8.69 billion CNY, reflecting its significant position within the industry.
In terms of financial performance, the company’s stock exhibited a close price of CNY 17.75 on February 23, 2026. Over the past year, the stock price has experienced fluctuations, with a 52-week high of CNY 23.18 recorded on June 3, 2025, and a 52-week low of CNY 16.21 on April 6, 2025. This range indicates a degree of price volatility, yet it remains within a relatively stable range, suggesting resilience in the face of broader market dynamics.
Recent corporate developments include the resolutions passed during the 19th meeting of the 8th Board of Directors, held on February 2, 2026. A significant outcome of this meeting was the appointment of new vice presidents, signaling potential strategic shifts or enhancements in leadership within the company. As of the latest updates, there have been no further announcements or changes reported.
For more information, stakeholders and interested parties can visit the company’s official website at www.guangyuyuan.cn . This platform provides additional insights into the company’s operations, product offerings, and corporate governance.
